It was reported in previous studies that prior exposure to topoisomerase II inhibitors may be associated with translocations involving KMT2A rearrangements and RUNX1 translocations [14,15,16], while monosomy of chromosome 5 or 7 or loss of 5q or 7q is characteristic of alkylating-agent-induced AML [14,15,17]. Here, RUNX1 is linked to acute myeloid leukemia.